DBV Technologies S.A. (DBVT)
Chart Events
Performance Outlook
| Previous Close | 2.5000 |
| Open | 2.4400 |
| Bid | 2.4100 x 1000 |
| Ask | 2.4300 x 3100 |
| Day's Range | 2.3700 - 2.5800 |
| 52 Week Range | 1.1500 - 5.9900 |
| Volume | |
| Avg. Volume | 747,027 |
| Market Cap | 275.686M |
| Beta (5Y Monthly) | 2.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York
Montrouge, France, June 16, 2022 DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, and Dr. Pharis Mohideen, Chief Medical Officer, will participate in a fireside chat on Thursday, June 16, 2022, at 12:00 p.m. ET at the JMP Securities Life Sciences Conference in New York. A we
- GlobeNewswire
DBV Technologies Announces Private Placement Financing of $194 Million
Montrouge, France, June 9, 2022 DBV Technologies Announces Private Placement Financing of $194 Million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT), a clinical-stage biopharmaceutical company, today announced an aggregate $194 million private investment in public equity (PIPE) financing (corresponding to €181 million on the basis of an exchange rate of $1.0739 = €1.00 published by the European Central Bank on June 8, 2022) from the sale of 32,855,669
- GlobeNewswire
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
Montrouge, France, June 7, 2022 DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers 67.0% of subjects treated with Viaskin Peanut 250 µg met response criteria at 12 months, compared with 33.5% of subjects in the placebo armPivotal trial met primary endpoint: lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 22.4%, exceeding the pre-specified threshold of 15%Safety results were gene
